Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Int J Gynaecol Obstet. 2023 Jan;160(1):313-318. doi: 10.1002/ijgo.14356. Epub 2022 Aug 8.
To investigate the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA BNT162b2 vaccine on women's menstrual cycle.
In this questionnaire-based cross-sectional study, we assessed menstrual pattern and changes in women who completed the SARS-CoV-2 mRNA BNT162b2 vaccine 3 months before and after receiving the vaccine. Included were women aged 18-50 years without known gynecologic comorbidities who regularly monitor their menstruation through electronic calendars. All participants competed a detailed questionnaire on their menstrual symptoms including information on any irregular bleeding. To minimize bias, each woman served as a self-control before and after vaccination. Primary outcome was rate of irregular bleeding following vaccination and secondary outcome was presence of any menstrual change, including irregular bleeding, mood changes, or dysmenorrhea following the vaccine.
A total of 219 women met the inclusion critieria. Of them, 51 (23.3%) experienced irregular bleeding following the vaccine. Almost 40% (n = 83) of study participants reported any menstrual change following vaccination. Parity was positively asssociated with irregular bleeding with 26 (50%) of those suffering from irregular bleeding being multiparous compared with only 53 (31.5%) of women with no irregular bleeding (nulliparous 46% vs 60%, multiparous 50% vs 31%, rest 4% vs 8%, P = 0.049). The presence of medical comorbidities was also significantly higher among patients who experienced irregular bleeding (20.0% vs 6.0%, P = 0.003).
Our study shows relatively high rates of irregular bleeding and menstrual changes after receiving the SARS-CoV-2 mRNA BNT162b2 vaccine. Further research is needed to confirm our findings and to better characterize the magnitude of change and any possible long-term implications.
研究严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)mRNA BNT162b2 疫苗对女性月经周期的影响。
本项基于问卷的横断面研究评估了接种 SARS-CoV-2 mRNA BNT162b2 疫苗前 3 个月和后 3 个月完成疫苗接种的女性的月经模式和变化。纳入标准为年龄在 18-50 岁之间、无已知妇科合并症、通过电子日历定期监测月经的女性。所有参与者均完成了关于月经症状的详细问卷,包括任何不规则出血的信息。为了最大程度地减少偏倚,每位女性在接种疫苗前后均作为自身对照。主要结局为接种疫苗后不规则出血的发生率,次要结局为接种疫苗后是否存在任何月经变化,包括不规则出血、情绪变化或痛经。
共有 219 名女性符合纳入标准。其中,51 名(23.3%)女性在接种疫苗后出现不规则出血。近 40%(n=83)的研究参与者报告接种疫苗后出现任何月经变化。产次与不规则出血呈正相关,26 名(50%)不规则出血患者为多产妇,而无不规则出血的女性中仅 53 名(31.5%)为多产妇(初产妇 46%比 60%,多产妇 50%比 31%,其余 4%比 8%,P=0.049)。不规则出血患者的合并症发生率也显著高于无不规则出血患者(20.0%比 6.0%,P=0.003)。
我们的研究表明,接种 SARS-CoV-2 mRNA BNT162b2 疫苗后不规则出血和月经变化的发生率相对较高。需要进一步研究来证实我们的发现,并更好地描述变化的幅度和任何可能的长期影响。